TrialHuman vaccines & immunotherapeutics2014

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.

Mark H Einstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.